No Data
Shareholder Wu Xihan of Pharma Block Sciences (300725.SZ) plans to reduce his shareholding by 0.37%.
Pharma Block Sciences (300725.SZ) announced that the company's shareholder Mr. Wu Xihan plans to ...
PharmaBlock Sciences (Nanjing)'s (SZSE:300725) Solid Earnings Have Been Accounted For Conservatively
Yakshi Technology: 2024 Annual Report Summary
Yakshi Technology: 2024 Annual Report
Yakshi Technology: First Quarter Report 2025
Jiangsu Aidea Pharmaceutical (688488.SH): project cooperation development framework contract terminated with Pharma Block Sciences.
On April 8th, Gelonghui reported that Jiangsu Aidea Pharmaceutical (688488.SH) announced that the company and its wholly-owned subsidiary Nanjing Aidea Pharmaceutical Technology Co., Ltd. signed the "Project Cooperation Development Framework Contract" (referred to as the "original framework contract") with Nanjing Pharma Block Sciences Co., Ltd. (hereinafter referred to as "Pharma Block Sciences" or "Party B") in August 2022 after friendly consultations. Both parties intend to jointly develop new drugs in the field of innovative targets and innovative compounds for 3CL protease inhibitors against the novel coronavirus pneumonia. Due to significant changes in the objective environment and market outlook of this project, both parties have reached a consensus through friendly negotiations to terminate the original framework contract and its annex in advance.
